Repression of transcription and interference with DNA binding of TATA-binding protein by C-terminal alternatively spliced p53

Experimental Cell Research

Volumn 279, Issue 2, 2002, Pages 248-259

  Huang, Hua ^a   Kaku, Shinsuke ^b   Knights, Chad D ^c   Park, Byung S ^c   Clifford, Jane ^d   Kulesz Martin, Molly ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

p53; TATA binding protein; Transactivation; Transcriptional repression; Waf 1

Indexed keywords

AMINO ACID; DNA; FUNCTIONAL GROUP; MESSENGER RNA; PROTEIN; PROTEIN P53; TATA BINDING PROTEIN;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA BINDING; DNA SEQUENCE; DNA SPLICING; GENE REPRESSION; GENETIC TRANSCRIPTION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFICIENCY; PROTEIN INTERACTION; PROTEIN PROCESSING; RNA SPLICING;

EID: 0036405612     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2002.5596     Document Type: Article

References (73)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. (1991). p53 mutations in human cancers. Science 253, 49-53.
2. Kastan, M. B., Zhan, Q., el Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J. J. (1992). A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597.
3. Barak, Y., Juven, T., Haffner, R., and Oren, M. (1993). mdm2 expression is induced by wild type p53 activity. EMBO J. 12, 461-468.
4. Wu, X., Bayle, J. H., Olson, D., and Levine, A. J. (1993). The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132.
5. Weintraub, H., Hauschka, S., and Tapscott, S. J. (1991). The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA 88, 4570-4571.
6. Zambetti, G. P., Bargonetti, J., Walker, K., Prives, C., and Levine, A. J. (1992). Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev. 6, 1143-1152.
7. Okamoto, K., and Beach, D. (1994). Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13, 4816-4822.
8. el Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
9. Gu, Y., Turck, C. W., and Morgan, D. O. (1993). Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366, 707-710.
10. Jeffrey, P. D., Gorina, S., and Pavletich, N. P. (1995). Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267, 1498-1502.
11. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. (1992). Regulation of the specific DNA binding function of p53. Cell 71, 875-886.
12. Hupp, T. R., Sparks, A., and Lane, D. P. (1995). Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 83, 237-245.
13. Lee, S., Elenbaas, B., Levine, A., and Griffith, J. (1995). p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81, 1013-1020.
14. Wu, L., Bayle, J. H., Elenbaas, B., Pavletich, N. P., and Levine, A. J. (1995). Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. Mol. Cell. Biol. 15, 497-504.
15. Bakalkin, G., Yakovleva, T., Selivanova, G., Magnusson, K. P., Szekely, L., Kiseleva, E., Klein, G., Terenius, L., and Wiman, K. G. (1994). p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA 91, 413-417.
16. Chen, X., Farmer, G., Zhu, H., Prywes, R., and Prives, C. (1993). Cooperative DNA binding of p53 with TFIID (TBP): A possible mechanism for transcriptional activation Genes Dev. 7, 1837-1849; Erratum: 7, 2652.
17. Sang, B. C., Chen, J. Y., Minna, J., and Barbosa, M. S. (1994). Distinct regions of p53 have a differential role in transcriptional activation and repression functions. Oncogene 9, 853-859.
18. Horikoshi, N., Usheva, A., Chen, J., Levine, A. J., Weinmann, R., and Shenk, T. (1995). Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13SE1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol. Cell. Biol. 15, 227-234.
19. Wu, Y., Huang, H., Miner, Z., and Kulesz-Martin, M. (1997). Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. Proc. Natl. Acad. Sci. USA 94, 8982-8987.
20. Fuchs, B., O'Connor, D., Fallis, L., Scheidtmann, K. H., and Lu, X. (1995). p53 phosphorylation mutants retain transcription activity. Oncogene 10, 789-793.
21. Jamal, S., and Ziff, E. B. (1995). Raf phosphorylates p53 in vitro and potentiates p53-dependent transcriptional transactivation in vivo. Oncogene 10, 2095-2101.
22. Milne, D. M., Campbell, D. G., Caudwell, F. B., and Meek, D. W. (1994). Phosphorylation of the tumor suppressor protein p53 by mitogen-activated protein kinases. J. Biol. Chem. 269, 9253-9260.
23. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. (1998). Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679.
24. Ullrich, S. J., Sakaguchi, K., Lees-Miller, S. P., Fiscella, M., Mercer, W. E., Anderson, C. W., and Appella, E. (1993). Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53. Proc. Natl. Acad. Sci. USA 90, 5954-5958.
25. Keller, D. M., Zeng, X., Wang, Y., Zhang, Q. O., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y., and Lu, H. (2001). A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol. Cell 7, 283-292.
26. Hupp, T. R., and Lane, D. P. (1994). Regulation of the cryptic sequence-specific DNA-binding function of p53 by protein kinases. Cold Spring Harbor Symp. Quant. Biol. 59, 195-206.
27. Wang, Y., and Prives, C. (1995). Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376, 88-91.
28. Sturzbecher, H. W., Maimets, T., Chumakov, P., Brain, R., Addison, C., Simanis, V., Rudge, K., Philp, R., Grimaldi, M., Court, W., and Jenkins, J. (1990). p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene 5, 795-801.
29. Lill, N. L., Grossman, S. R., Ginsberg, D., Decaprio, J., and Livingston, D. M. (1997). Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823-826.
30. Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., and Kelly, K. (1997). Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89, 1175-1184.
31. Milne, D. M., Palmer, R. H., and Meek, D. W. (1992). Mutation of the casein kinase II phosphorylation site abolishes the anti-proliferative activity of p53. Nucleic Acids Res. 20, 5565-5570.
32. Hall, S. R., Campbell, L. E., and Meek, D. W. (1996). Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. Nucleic Acids Res. 24, 1119-1126.
33. Mundt, M., Hupp, T. R., Fritsche, M., Merkle, C., Hansen, S., and Lane, D. (1997). Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential. Oncogene 15, 237-244.
34. Ginsberg, D., Mechta, F., Yaniv, M., and Oren, M. (1991). Wild-type p53 can downmodulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88, 9979-9983.
35. Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M., and Aloni, Y. (1993). Wild-type but not mutant p53 can repress transcription initiation in vitro by interfering with the binding of basal transcription factors to the TATA motif. Oncogene 8, 1183-1193.
36. Iotsova, V., Crépieux, P., Montpellier, C., Laudet, V., and Stehelin, D. (1996). TATA-less promoters of some Ets-family genes are efficiently repressed by wild-type p53. Oncogene 13, 2331-2337.
37. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tlsty, T. D., Lees, E., Harper, J. W., Elledge, S. J., and Reed, S. I. (1994). p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023.
38. Yamamoto, M., Yoshida, M., Ono, K., Fujita, T., Ohtani Fujita, N., Sakai, T., and Nikaido, T. (1994). Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression. Exp. Cell Res. 210, 94-101.
39. Mercer, W. E., Shields, M. T., Lin, D., Appella, E., and Ullrich, S. J. (1991). Growth suppression induced by wild-type p53 protein is accompanied by selective downregulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA 88, 1958-1962.
40. Sabbatini, P., Chiou, S.-K., Rao, L., and White, E. (1995). Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15, 1060-1070.
41. Shen, Y., and Shenk, T. (1994). Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc. Natl. Acad. Sci. USA 91, 8940-8944.
42. Liu, X., Miller, C. W., Koeffler, P. H., and Berk, A. J. (1993). The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription. Mol. Cell. Biol. 13, 3291-3300.
43. Scto, E., Usheva, A., Zambetti, G. P., Momand, J., Horikoshi, N., Weinmann, R., Levine, A. J., and Shenk, T. (1992). Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89, 12028-12032.
44. Léveillard, T., Andera, L., Bissonnette, N., Schaeffer, L., Bracco, L., Egly, J. M., and Wasylyk, B. (1996). Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations. EMBO J. 15, 1615-1624.
45. Mack, D. H., Vartikar, J., Pipas, J. M., and Laimins, L. A. (1993). Specific repression of ATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 363, 281-283.
46. Agoff, S. N., Hou, J. H., Linzer, D. I. H., and Wu, B. (1993). Regulation of the human hsp70 promoter by p53. Science 259, 84-87.
47. Wang, Q., Zambetti, P., and Suttle, D. P. (1997). Inhibition of DNA topoisomerase IIa gene expression by the p53 tumor suppressor. Mol. Cell. Biol. 17, 389-397.
48. Han, K. A., and Kulesz Martin, M. F. (1992). Alternatively spliced p53 RNA in transformed and normal cells of different tissue types. Nuleic Acids Res. 20, 1979-1981.
49. Kulesz-Martin, M. F., Lisafeld, B., Huang, H., Kisiel, N. D., and Lee, L. (1994). Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol. 14, 1698-1708.
50. Wolf, D., Harris, N., Goldfinger, N., and Rotter, V. (1985). Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol. Cell. Biol. 5, 127-132.
51. Wu, Y., Liu, Y., Lee, L., Miner, Z., and Kulesz-Martin, M. (1994). Wild-type alternatively spliced p53: Binding to DNA interaction with the major p53 protein in vitro and in cells. EMBO J. 13, 4823-4830.
52. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830.
53. Blake, M. C., Jambou, R. C., Swick, A. G., Kahn, J. W., and Azizkhan, J. C. (1990). Transcriptional initiation is controlled by upstream GC-box interactions in a TATAA-less promoter. Mol. Cell. Biol. 10, 6632-6641.
54. Chiang, S. Y., Welch, J., Rauscher, F. J., III, and Beerman, T. A. (1994) Effects of minor groove binding drugs on the interaction of TATA box binding protein and TFIIA with DNA. Biochemistry 33, 7033-7040.
55. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). "Molecular Cloning, A Laboratory Manual," 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
56. Pierce, A. J., Jambou, R. C., Jensen, D. E., and Azizkhan, J. C. (1992). A conserved DNA structural control element modulates transcription of a mammalian gene. Nucleic Acids Res. 20, 6583-6587.
57. Kuehl, R. O. (1994). "Statistical Principles of Research Design and Analysis," Wodsworth, Belmont, CA.
58. Cayrol, C., and Ducommun, B. (1998). Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21. Oncogene 17, 2437-2444.
59. Zawel, L., and Reinberg, D. (1993). Initiation of transcription by RNA polymerase II: A multi-step process. Prog. Nucleic Acid Res. Mol. Biol. 44, 67-108.
60. Lin, J., Teresky, A. K., and Levine, A. J. (1995). Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants. Oncogene 10, 2387-2390.
61. Farmer, G., Colgan, J., Nakatani, Y., Manley, J. L., and Prives, C. (1996). Functional interaction between p53, the TATA-binding protein (TBP), and TBP-associated factors in vivo. Mol. Cell. Biol. 16, 4295-4304.
62. Farmer, G., Friedlander, P., Colgan, J., Manley, J. L., and Prives, C. (1996). Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res. 24, 4281-2888.
63. Miner, Z., and Kulesz-Martin, M. (1997). DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs. Nucleic Acids Res. 25, 1319-1326.
64. Deffie, A., Wu, H., Reinke, V., and Lozano, G. (1993). The tumor suppressor p53 regulates its own transcription. Mol. Cell. Biol. 13, 3415-3423.
65. Almog, N., Milyavsky, M., Stambolsky, P., Falcovitz, A., Goldfinger, N., and Rotter, V. (2001). The role of the C terminus of murine p53 in the p53/mdm-2 regulatory loop. Carcinogenesis 22, 779-785.
66. Espinosa, J. M., and Emerson, B. M. (2001). Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell 8, 57-69.
67. Shaulian, E., Haviv, I., Shaul, Y., and Oren, M. (1995). Transcriptional repression by the C-terminal domain of p53. Oncogene 10, 671-680.
68. Laverdiere, M., Beaudoin, J., and Lavigueur, A. (2000). Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. Nucleic Acids Res. 28, 1489-1497.
69. II 31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci. USA 92, 5154-5158.
70. II 60. Science 267, 100-104.
71. Martin, D. W., Munoz, R. M., Subler, M. A., and Deb, S. (1993). p53 binds to the TATA-binding protein-TATA complex. J. Biol. Chem. 268, 13062-13067.
72. Kaku, S., Iwahashi, Y., Kuraishi, A., Albor, A., Yamagishi, T., Nakaike, S., and Kulesz-Martin, M. (2001). Binding to the double p53-binding site of the Mdm2 promoter alleviates the requirement for p53 carboxy-terminal activation. Nucleic Acids Res. 29, 1989-1993.
73. Wolkowicz, R., Peled, A., Elkind, N. B., and Rotter, V. (1995). Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proc. Natl. Acad. Sci. USA 92, 6842-6846.